, Dec. 7, 2010
/PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia
) for access to its fluorescent proteins. This license allows Cellectis bioresearch to incorporate these proteins into its own products and will expand the company's offering of genome engineering tools.
Luc Selig, Sales and Marketing Director of Cellectis bioresearch, commented, "One of the key components of our kits is the integration matrix which enables the user to express a gene of interest. By extending the choice of promoters and tags in these matrices, we can offer our clients a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."
Cellectis bioresearch develops and commercializes ready- and easy-to-use tools and technologies for the life science industry. These tools can be used to customize any cell for drug development, protein production or functional genomics. To date, Cellectis bioresearch markets over one hundred products through its online store and international distribution network and sales forces.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The kits can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.
More information atwww.cellectis.com.
Follow Cellectis on Twitter at www.twitter.com/cellectis.
Evrogen is an innovation-driven company founded by scientists and dedicated to making successful ideas widely available as efficient products and services for life science research.
More information at www.evrogen.com.
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis bioresearch